Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib monotherapy or apatinib plus capecitabine for advanced breast cancer
ChiCTR1800014477Phase 4Not yet recruiting
- Sponsor
- Suining Central Hospital
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and capecitabine in breast cancer, sponsored by Suining Central Hospital. Primary endpoints: progression-free survival, objective response rate and 1 more. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1800014477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014477.